CN-122012414-A - Klebsiella pneumoniae phage vB_ KpnM _pha0233 and application thereof

Abstract

The invention discloses a Klebsiella pneumoniae phage vB_ KpnM _pha0233 and application thereof, belonging to the technical field of microorganisms. Klebsiella pneumoniae phage (Klebsiella pneumoniae phage) vB_ KpnM _pha0233 was deposited at the Cantonese institute of microorganisms and cell cultures, accession No. GDMCC NO:67292-B1, accession No. Cantonese institute of sciences of Cantonese, 11 and 13. The phage has high adsorption rate of 92% to Klebsiella pneumoniae, short incubation period, high progeny burst of single host bacteria, high-efficiency amplification and quick bacteriostasis under extremely low MOI (0.00001), good pH and temperature tolerance, and adaptation to complex environments, and genome analysis shows that the phage is a brand new strain, does not contain resistance genes, has low toxicity risk, has good biological safety, and is suitable for various bacteria control scenes such as agriculture, environmental protection, clinic and the like.

Inventors

• LIN JUN
• WANG QINGQING

Assignees

• 福州大学

Dates

Publication Date

20260512

Application Date

20260228

Claims (6)

1. 1. A phage is characterized in that the phage is Klebsiella pneumoniae phage (Klebsiella pneumoniae phage) vB_ KpnM _pha0233, and is deposited in the microorganism strain collection of Guangdong province on the 11 th month 13 of 2025, the deposit number is GDMCC NO:67292-B1, and the deposit address is the microorganism research institute of the Guangdong province academy of sciences.
2. 2. Use of klebsiella pneumoniae phage vb_ KpnM _pha0233 according to claim 1 in the manufacture of a medicament for the treatment of a disease caused by klebsiella pneumoniae.
3. 3. The use of klebsiella pneumoniae bacteriophage vb_ KpnM _pha0233 according to claim 1 in the preparation of a klebsiella pneumoniae bacteriostat.
4. 4. The use according to claim 3, wherein the bacteriostatic agent is used in the food preservation, environmental disinfection, livestock breeding, poultry breeding, aquaculture, water treatment or biomedical industry.
5. 5. A phage preparation, characterized in that, comprising the klebsiella pneumoniae phage vb_ KpnM _pha0233 of claim 1.
6. 6. The phage preparation according to claim 5, further comprising a buffer as a stabilizer, wherein the buffer is DPBS buffer, physiological saline, SM buffer or glycerol solution.

Description

Klebsiella pneumoniae phage vB_ KpnM _pha0233 and application thereof Technical Field The invention belongs to the technical field of microorganisms, and particularly relates to a Klebsiella pneumoniae phage vB_ KpnM _pha0233 and application thereof. Background Klebsiella pneumoniae (Klebsiella pneumoniae, kp) belongs to the family enterobacteriaceae, originally called Friedlander's bacteria, is a gram-negative, motile-free, encapsulated bacterium that is present in soil, surface water and other environments and is commonly parasitic on the skin, respiratory tract, intestinal tract and the like of humans and animals. Kp is an opportunistic pathogen, most likely to infect immunocompromised individuals in a hospital setting, and is one of the few gram-negative bacilli that can cause primary pneumonia, and is also the primary cause of hospital-acquired pneumonia (HAP), and can cause, but is not limited to, sepsis, meningitis, and Urinary Tract Infection (UTI) that lead to serious organ damage and life threatening diseases. At present, antibiotics are mainly used clinically for treating Kp infection, including quinolones, beta-lactams (penicillins, cephalosporins, carbapenems), aminoglycosides, polymyxins and other various medicines, but Kp has natural resistance to penicillin, and population members generally have acquired resistance to various antibiotics. With the wide clinical application of antibiotics, kp has gradually increased in the drug resistance rate against the aforementioned various clinically common antibiotics, has shown a trend of multiple drug resistance, has been increasingly common in the phenomena of high toxicity and overlapping of high drug resistance, and has been increasingly popular with the trend of diversification and globalization. Until now, even the so-called "last line of defense" carbapenem antibiotics have been broken through against klebsiella pneumoniae, and the proportion of carbapenem-resistant klebsiella pneumoniae has been increased year by year. Meanwhile, polymyxin is highly sensitive to most gram-negative bacilli as an alkaline polypeptide antibacterial agent, but has limited application due to its neurotoxicity and nephrotoxicity. In view of the fact that the current severe drug-resistant situation and the development speed of new drugs cannot meet the clinical demands, polymyxin is paid attention again and is regarded as the last means for treating carbapenem-resistant gram-negative bacilli, but the phenomenon that part of Kp is resistant to polymyxin also occurs. Therefore, the search for alternative drugs and strategies to treat drug-resistant Kp infections has become indispensable, and in the case of a substantial increase in multi-drug-resistant Kp, phages have been regarded as potential drugs to treat clinical infections. Phage (Bacteriophages, phages) is a virus that specifically infects bacterial hosts, originally isolated to target pathogens, phage therapy is defined as the direct administration of toxic phage to patients, with the aim of lysing bacterial pathogens that cause clinically relevant infections, a research anti-infective therapy against refractory, multi-drug resistant and/or biofilm-mediated infections. As a natural antibacterial agent, the phage is abundant in nature, easy to obtain, low in cost of separation and purification and inherent toxicity, and very suitable for becoming part of multidimensional strategies against antibiotic resistance. Clinically, in order to overcome the problem of drug resistance and enhance the treatment effect, phage therapy is often used as a substitute or auxiliary treatment means for the traditional antibiotic therapy, has similarities with the antibiotic therapy, and has unique treatment advantages. Disclosure of Invention Aiming at the technical limitations, the invention provides a Klebsiella pneumoniae phage vB_ KpnM _pha0233 and application thereof. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: The invention firstly provides a phage, wherein the phage is Klebsiella pneumoniae phage (Klebsiella pneumoniae phage) vB_ KpnM _pha0233 which is preserved in the microorganism strain preservation center of Guangdong province on the 11 th month 13 of 2025, the preservation number is GDMCC NO:67292-B1, and the preservation address is the microorganism research institute of the Guangdong province academy of sciences. According to the invention, 1 strain of klebsiella pneumoniae phage vB_ KpnM _pha0233 with high cracking activity, environmental stability and safety is screened from natural environment, and the phage can specifically identify and crack klebsiella pneumoniae so as to clear infection, and the problem of antibiotic resistance of the klebsiella pneumoniae is solved. The invention also provides the application of the klebsiella pneumoniae phage vB_ KpnM _pha0